Article Sidebar

Submitted
May 22, 2021
Accepted
May 22, 2021
Published
May 22, 2021
Download
PDF
Statistic
Read Counter : 351 Download : 241

Main Article Content

Abstract

Objective: Erectile dysfunction (ED) is a common enough male problem. It is secondary to organic, psychogenic and combined causes. This study described the normal sonographic anatomy of the penis, sonographic technique for evaluation of ED and the normal phases of erection with intracavernousal injection (ICI) of alprostadil (coverject®).
Patients and methods: Twenty five diabetic patients (on oral hypoglycemic drugs for at least 10 year) complaining of prolonged history (>2 years) of ED, aged 35 to 45 years, were included in this study. The treatment started with a minimal dose of 1.125 micrograms and the dosage was titrated to achieve rigid erection. Following the establishment of the effective dose, Doppler US examinations were performed.
Results: 21 patients (84%) had a grade IV erectile response, the remaining 4 patients (16%)have grade III. A significant increase in peak systolic velocity between baseline and 20 µg PGE1 (p<0.001) was observed in all cases. Following ICI of Coverject there was a significant increase in grade of erection (p<0.001) and a significant reduction in the end diastolic volume (EDV) (p<0.001). A reduction of the EDV to below 5 cm s–1 was observed in all patients. Four patients with EDV <5.0 cm s–1 but >0.0 cm s–1 had poor erectile response following ICI while 21 showed persistent EDV reduction  <5 cm s–1 with good rigidity.
Conclusion: the important cause of ED in the diabetic patient is psycogenic factor and Intracavernous injections of Caverject are effective therapy for erectile dysfunction

Article Details

References

  1. NIH Consensus Conference: Impotence: NIH Consensus Development Panel on Impotence. JAMA 1993; 270:83-90.
  2. Feldman HA, Goldstein I, Hatzichriston DG, Krane RJ, Mc Kinley JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54-61.
  3. Anderson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75:191-236.
  4. Lue TF. Erectile dysfunction. New Engl J Med. 2000; 342:1802-1813.
  5. . McCulloch DK, Campbell IW, Wu FC, P rescott RJ, Clarke BF: The prevalence of diabetic impotence. D i a b e t o l o g i a1 8 : 2 7 9 – 2 8 3 , 1 9 8 0
  6. Schiavi RC, Stimmel BB, Mandeli J, Rayfield EJ: Diabetes mellitus and male sexual function: a controlled study. D i a b e t o l o g i a 36:745–751, 1993
  7. Rosen MP, Greenfi eld AJ, Walker TG et al (1991) Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 145: 759–763.
  8. Rajfer J, Rosciszewski A, Mehringer M (1988) Prevalence of corporeal venous leakage in impotent men. J Urol 140: 69–71.
  9. Christ GJ, Maayani S, Valcic M et al (1990) Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol 101: 375–381.
  10. Padma-Nathan H, Hellstrom WJ, Kaiser FE et al (1997)Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 336:1–7
  11. -Sakamoto H, Nagata M, Saito K, Okumura T, Yoshida H. Anatomic variations of cavernous arteries and their effect on measurement of hemodynamic parameters: a power Doppler study. Urology. 2004 Mar;63(3):539-44.
  12. Junuzović D, Mehmedbasić S, Smajlović F.Color-Doppler ultrasonography in the diagnostic evaluation of erectile dysfunction. Med Arh. 2003;57(5-6):279-83.
  13. Musaed F., Maria K., Mohammed A., Tiberiu R . Intracavernous Injection of Prostaglandin E1 for the Treatment of Erectile Dysfunction in Spinal Cord Injured Patients: Experience with 30 Patients; Kuwait Medical Journal 2005, 37 (1): 33-37.
  14. Virag R, Frydman D, Legman M. Intracavernous injection of papaverine as diagnostic and therapeutic method in erectile failure. Angiology 1984;35:79–83.
  15. Karadeniz T, Ariman A, Topsakal M, et al. Value of colour Doppler sonography in the diagnosis of venous impotence. Urol Int 1995;55:143–9.
  16. Mellinger BC, Fried JJ, Vaughn ED. Papaverine-induced penile blood flow acceleration in impotent men measured by duplex scanning. J Urol 1990;144:897–903.
  17. Ahn HS, Lee SW, Yoon SJ, Hann HJ, Hong JM. A comparison of colour duplex ultrasonography after transurethral alprostadil and intracavernous alprostadil in the assessment of erectile dysfunction dysfunction. J Int Med Res. 2004 May-Jun;32(3):317-23.
  18. Wespes E. Diagnosis and treatment of venous impotence. Curr Opin Urol 1991;1:140–7.
  19. Saenz de Tejada I, Goldstein I, Krane RJ. Nerves, smooth muscles and endothelium. Review of local control of the intracavernous smooth muscle. Urol Clin N Am 1988;15:9–15.
  20. Mellinger BC, Fried JJ, Vaughn ED. Papaverine-induced penile blood flow acceleration in impotent men measured by duplex scanning. J Urol 1990;144:897–903.
  21. Kropman RF, Schipper J, van Ostayen JA, et al. The value of increased end-diastolic velocity during penile duplex sonography in relation to pathological venous leakage in erectile dysfunction. J Urol 1992;148:314–9.
  22. Akkus E, Ahci B, Ozkara H, et al. Repetition of colour Doppler ultrasonography: is it necessary. Int J Impot Res 1998;10:51–6.
  23. Merckx LA, De Bruyne RM, Goes E, et al. The value of dynamic colour Duplex scanning in the diagnosis of venogenic impotence. J Urol 1992;148:318–22.
  24. BacarMM, Batislam E, Altinok D, et al. Sildenafil citrate for penile hemodynamic determination: an alternative to intracavernosal agents in Doppler ultrasound evaluation of erectile dysfunction. Urology 2001;57:623–627.
  25. MeulemanEJ, Diemont WL. Investigation of erectile dysfunction: diagnostic testing for vascular factors in erectile dysfunction. Urol Clin North Am 1995;22:803–819.
  26. Araujo AB, Durante R, Feldman HA et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom. Med. (1998) 60: 458–465.
  27. Shabsigh R, Klein LT, Seidman S et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology (1998) 52: 848–852.
  28. Corona G, Mannucci E, Mansani R et al. Aging and pathogenesis of erectile dysfunction. Int. J. Impot. Res. (2004). 16: 395–402.
  29. Angulo J, Cuevas P, Gabancho S et al Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. J Sex Med(2005) 2: 341–346.
  30. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch. Sex. Behav. (1983) 12: 59–66
  31. Rosen MP, Greenfi eld AJ, Walker TG et al.Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J. Urol. (1991) 145: 759–763.
  32. Levine FJ, Greenfi eld AJ, Goldstein I. Arteriographically determined occlusive disease within the hypogastric- cavernous bed in impotent patients following blunt perineal and pelvic trauma.. J.Urol. (1990)144: 1147–1153.
  33. Rajfer J, Rosciszewski A, Mehringer M. Prevalence of corporeal venous leakage in impotent men. J Urol (1988) 140: 69–71.
  34. Christ GJ, Maayani S, Valcic M et al. Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol (1990)101: 375–381.
  35. Aversa A, Rocchietti-March M, Caprio M, Giannini D, Isidori A, Fabbri A. Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: a new diagnostic approach. Int J Androl 1996;19:307–13.
  36. Montorsi F, Guazzoni G, Barbieri L, et al. The effect of intracorporeal injection plus genital and audiovisual sexual stimulation versus second injection on penile color Doppler sonography parameters. J.Urol. 1996;155:536–40.